Multivalent antibody recruiting molecules as a novel type of cancer immunotherapy.

Uvyn, Annemiek
Faculteit Farmaceutische Wetenschappen
Vakgroep Geneesmiddelenleer
Master of Science in Pharmaceutical Care (magna cum laude), Universiteit Gent, 5 juli 2017
Academische graad
Doctor in de farmaceutische wetenschappen
Taal proefschrift
Vertaling titel
Multivalente antilichaam rekruterende moleculen als een nieuwe vorm van immunotherapie voor kanker.
Prof. dr. Bruno De Geest, UGent-Geneesmiddelenleer
Prof. dr. Aurélie Crabbé, UGent-Farmaceutische Analyse - Dr. Benoit Louage, UGent-Geneesmiddelenleer - Prof. dr. Li Tang, Ecole polytechnique fédérale de Lausanne - Prof. dr. Bert Meijer, Technische Universiteit Eindhoven - Dr. Ruben De Coen, eTheRNA Immunotherapies - Dr. Lutz Nuhn, Max Planck Institute for Polymer

Korte beschrijving

The general aim of this thesis is to design multivalent antibody recruiting molecules. ARMs are synthetic bifunctional molecules which can introduce antibodies onto a disease-relevant target. As an alternative to the use of externally administered mAbs, exploiting the presence of endogenous antibodies that are present in the serum of every human being could be attractive. ARMs consist of a target binding terminus (TBT) which can interact with a pathogen or cancer cell surface and a hapten as an antibody binding terminus (ABT) that can bind endogenous anti-hapten antibodies. By doing so, a ternary complex is formed between the pathogen or cancer cell of interest, the ARM and the antibody. The subsequent clustering of antibodies on a target surface is capable to induce antibody-mediated immune responses including ADCC, CDC and ADCP, to kill the target. The design of multivalent macromolecules consisting of multiple ABTs and/or TBTs could be an added value in efficiently recruiting antibodies towards a cell surface and subsequent induction of innate cell killing.


Maandag 29 november 2021, 18:30
Aula, Ceremoniezaal, Voldersstraat 9, 9000 Gent
Volg online